ChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript November 8, 2023

ChromaDex Corporation beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.03.

Operator: Hello and thank you for standing by. My name is Regina and I'll be your conference operator today. At this time, I'd like to welcome everyone to the ChromaDex Corporation Third Quarter 2023 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks there’ll be a question and answer session. [Operator Instructions]. I would now like to turn the conference over to Kendall Knysch, Head of Public Relations and partnerships. Please go ahead.

Kendall Knysch: Thank you. Good afternoon and welcome to ChromaDex Corporation's third quarter 2023 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried, Chief Financial Officer, Brianna Gerber, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao, who will join the call for Q&A. Today's conference call may include forward-looking statements, including statements related to ChromaDex's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Tru Niagen in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest, and business prospects and opportunities, as well as anticipated results of operations.

Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause ChromaDex’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These risk factors include those contained in ChromaDex’s quarterly reports on Form 10-Q most recently filed with the SEC, including results of operations, financial condition, cash flows, adverse global market and economic conditions on our business. Please note that the company assumes no obligation to update any forward-looking statements after the date of this conference call to conform with the forward-looking statements, actual results, or to changes in its expectations.

In addition, certain of the financial information presented in this call references non-GAAP financial measures. The company's earnings presentation and earnings press release, which were issued this afternoon and are available on the company's website, presents reconciliations to the appropriate GAAP measures. Finally, this conference call is being recorded via webcast. The webcast will be available at the Investor Relations section of our website at www.chromadex.com. With that, it is now my pleasure to turn the call over to our Chief Executive Officer, Rob Fried.

Rob Fried: Thanks, Kendall. Good afternoon, everyone. And thank you for joining us on today's investor call. For the third quarter we delivered another solid quarter with $19.5 million in revenue a 14% increase year-over-year, coupled with another quarter of positive adjusted EBITDA of $500,000 and net positive operating cash flow of $400,000. Year-to-date revenues are up 22% and we have generated $6.5 million of positive cash flow from operations. We ended the third quarter with $26.8 million in cash and no debt. These continued achievements are a testament to our commitment in maintaining fiscal discipline and driving profitable growth for the business. The E-commerce business continues to be our largest and most consistent source of revenue.

E-commerce net revenue is up 13% year-over-year as our marketing team continues to focus on initiatives and campaigns that drive direct and efficient returns. For the total company sales and marketing expense was 31% of net revenues, which was down sequentially and a significant reduction from 34.4% in the prior year quarter. We recognize that building a strong subscription based on our own website is critical to driving long term customer value and we have identified important fundamental changes to rebuild this growth engine for business. To deliver on this key objective for 2024, we will look to increase resources to optimize our retention strategy, our content and our social media presence. Beginning in the fourth quarter. We will also look to increase resources to support the launch of new innovations in 2024.

Of course, with any transition it will take time for the improvements in strategy and execution to be reflected in the net revenues and further efficiencies, we remain committed to being disciplined in our investments. And we believe that the resources we are investing in will amplify our message and our vision that ChromaDex is the gold standard in the NAD space and Tru Niagen continues to be the best NAD product on the market. Turning to our strategic partnerships, Watson's remains a strong contributor to growth with third quarter revenues of $3.1million, a 19% increase year-over-year. As I mentioned last quarter, Watson's has been promoting the stacking concept which involves combining Tru Niagen with Tru Niagen immune and or Tru Niagen beauty.

This continues to be an effective message for consumers. We're exploring the opportunity to better implement the staffing concept in other markets to similarly promote the Tru Niagen immune product. The partnership with Sinopharm in China remains one of great opportunity and importance, the process to pursue Blue Hat approval continues to take longer than anticipated. But that is not stopping our teams from continuing to work closely with Sinopharm to execute campaigns and initiatives to capture the market opportunity in the country, encouragingly, last month, Tru Niagen was featured as the best NR supplement in 2023. In an article to Health Products Association, China. Last quarter, I highlighted our new partnership with iHerb. While the partnership is still in the early stages of growth, we have been pleased with the performance so far.

As expected around 80% of Tru Niagen’s sales through iHerb has been to international consumers. We continue to be optimistic in the partnership with iHerb to drive expands an international presence for Tru Niagen and are actively working with them on campaigns to feature our brand more prominently on the platform. With our Niagen ingredient partners, there are two significant milestones I'd like to announce. First, we are partnering with Zesty Paws the number one selling pet supplement brand in the U.S to make Niagen available to benefit the healthy aging for dogs. With the launch of the Healthy Aging NAD plus precursor. We're proud to partner with Zesty Paws, to extend the benefit of Niagen to all members of our family's including our canine companions.

As the global authority on NAD, and healthy aging research, this is a breakthrough in the company's mission to improve as many lives as possible with the transformative power of Niagen. While we are in the early stages of the first product launch, we look forward to future innovations in the pet supplement space, in partnership with Zesty Paws who placed the second order of Niagen last month. Second, Nestle Health Science launched its Solgar cellular nutrition line of supplements, featuring a multi ingredient product that incorporates Niagen to support cell energy, repair and vitality. The cellular energy product combines Niagen with sources of vitamin C and D to support energy metabolism, immune heart and nerve health. It is inspiring and encouraging to continue to work with the passionate teams at Nestle to launch innovative products to optimize cellular health and promote longevity.

I look forward to announcing future innovative product launches under the Nestle Health science portfolio of well-known brands. And finally, we are pleased to announce the launch of our Tru Niagen Pro 1000 milligram product line introducing a clinical strength dose. That empowers consumers to improve their NAD levels in a more efficient and more efficacious way. Among published clinical studies to date, the most extensively researched daily dose of Niagen is 1000 milligrams with 2000 milligrams is the highest dose with established safety. 1000 milligram dosage has been clinically proven to be safe elevating NAD levels up to 150% after just two weeks, compared to 40% to 50% improvement in NAD levels with the 300 milligram daily dosage. We're excited to introduce this new addition to our product portfolio aimed at consumers looking to take aging into their own hands and improve their livelihoods.

ChromaDex continues to be in its strongest financial position to date, and we're building momentum toward growth opportunities. While certain commercial opportunities are taking more time to unlock, I'm impressed with the progress in our innovation pipeline. Brianna will touch on the updated outlook for 2023. But I'm increasingly confident that we are setting the stage for further growth opportunities in 2024 and beyond. We're building on our powerful scientific foundation as the world's leading NAD Company maintaining our position as a paragon of scientific integrity. Through the ChromaDex External Research program or CERP, we continue to foster a relationship of trust and integrity in the scientific community. And we continue to drive scientific innovation.

Since our last update for additional human trials on nicotinamide right beside had been registered, one of which I want to highlight that aims to explore how NR effects the energy and immune related features of specific immune cells, myeloid cells in different populations. Inflammation or the concept of inflamaging remains an important area of research on how NR complain active and beneficial role in reducing inflammation as a healthy aging benefit. In August the results of a clinical study published in the peer reviewed journal Cell reports indicated that NR was successful in inflammation in both healthy subjects and in cells derived from psoriasis patients. This marks a significant achievement in NAD research, as they further validate NR is the proactive safeguard against inflammatory cytokines and healthy individuals and in those with inflammation related disorders.

To further emphasize the magnitude of this study, Healio, a leading medical media company and trusted platform physicians and healthcare professionals, featured the results of the study along with commentary from Dr. Charles Brenner. In addition, the results of a clinical study that investigated the safety benefits of long term NR supplementation in individuals with Ataxia, a rare genetic neurodegenerative disorder, republished in October. Previous studies have shown that NAD deficiency plays a role in disease mechanisms underlying DNA repair disorders, such as AT. The results of this clinical study build on those from a previously published short term trial and confirm that long term supplementation of NR was safe and well tolerated and improved motor coordination and eye movements in patients with AT of various ages.

CERP remains committed to conducting research to uncover different ways Niagen can benefit consumers including therapeutic benefits for consumers coping with different ailments. Today we have announced two published peer reviewed clinical studies on Parkinson's disease by a group of researchers led by Dr. Tzoulis this one of our esteemed CERP investigators. A third study of Parkinson's disease by Dr. Tzoulis lab was recently completed. This study investigated the safety of supplementing 3000 milligrams per day of NR to PD patients. The highest dose studied to-date. We eagerly await publication of the study results and are excited to share more in future updates. At ChromaDex, we continue to work with esteemed leaders in the field of aging. Earlier this year, we announced the appointment of leading aging and neurodegenerative disease researcher Dr. Vilhelm Bohr to our Scientific Advisory Board.

Dr. Bohr joins a distinguished board which includes two chemistry Nobel Prize winners and Dr. Roger Kornberg, and Professor Sir John Walker, and includes the world's foremost authority on NAD metabolism. Dr. Charles Brenner. In October, the National Academy of Medicine announced that Dr. Rudolph Tanzi, another member of our Scientific Advisory Board, was elected as a member of the Academy, recognizing his contributions as a pioneer and leader in research in Alzheimer's disease. We applaud his achievement as the election to the academy is recognized as one of the highest honors in the field of health and medicine. We continue to defend our achievements and inventions and to take action to prevent infringement. As mentioned in our prior calls, last year we were granted a series of new critical patents, which in combination with existing IP and patents from W.R. Grace, was supplied to ChromaDex exclusively for the last decade.

An aisle lined with shelves of fresh and frozen foods in a supermarket store.

We protect our NR IP for at least the next decade. Last month, the jury in the U.S District Court of Delaware decisively found that Elysium Health fully infringed W.R. Grace patents protecting NR supplied exclusively to ChromaDex. Additionally, I'm proud to announce that we have extended our 10-year collaboration with W.R, Grace to continue delivering the highest quality NAD precursor in the world. Finally, I want to briefly comment on the recent favorable decision to ChromaDex in the U.S District Court of Appeals in New York. The Court affirmed that our settlement with Elysium is enforceable. We look forward to collecting the $2.5 million that Elysium owes, plus the terms of the settlement and putting this behind us. At ChromaDex, we are all true believers and are extremely passionate about bringing NR to consumers in innovative ways to benefit their lives.

The partnership with Zesty Paws as I mentioned is a start for our company to extend NR as a benefit beyond human supplementation. We also continue to have untapped potential and NAD precursors beyond NR, which are protected by ChromaDex’s deep intellectual property portfolio. Some of these novel NAD precursors may have some significant prophylactic and therapeutic value in the pharmaceutical space. We will continue to use our position as the global authority in NAD science and as a trusted partner to researchers, regulatory authorities and world class business partners to drive innovation and improve as many lives as possible. While certain R&D innovations have been in development for quite some time and may take a little bit longer to commercialize.

We are excited as we look to the future. We look forward to sharing more details on future updates. I would now like to turn the call over to Brianna to discuss the quarter’s results in more detail. And then on to Q&A and closing remarks. Brianna?

Brianna Gerber : Thank you Rob. Now that we've covered the broader strategic landscape and operational overview, I'm excited to delve into the specifics of our third quarter financial results, which showcase our commitment to balance top and bottom line growth and overall operational discipline. Highlighting the key metrics of our third quarter performance, ChromaDex delivered total net sales as $19.5 million up 14% robust gross margins of 61.4%, a reduction in overall operating expenses and a net loss of only $1 million. Additionally, our adjusted EBITDA a non-GAAP metric was a positive $0.5 million a $1.7 million improvement year-over-year. Net sales are up 22% year-to-date, with an adjusted EBITDA $0.7 million and positive operating cash flow of $6.5 million.

Our performance this quarter underscores our relentless pursuit as efficiency across the organization to position the business for sustainable growth and profitability. The consistent results we have achieved speak to the resilience of our business model, and we are proud of the progress we've made today. With that, let's turn to the third quarter financials in more detail. As I said total net sales in the third quarter of 2023 were up 14% year-over-year, as compared to the third quarter of 2022, with a 19% increase in Tru Niagen driven by 13% growth in E-commerce sales, fueled by continued growth on Amazon, including a strong performance on Prime Day, paired with 43% growth in combined Watson's and other B2B sales. Watson sales were higher year-over-year as the COVID-19 and macroeconomic challenges abated coupled with reorders for Tru Niagen immune following a positive initial launch response from consumers last quarter.

We also benefited from sales with new partners like iHerb and ShopHQ which were not in the prior year period. On that note, ShopHQ parent company iMedia brand has successfully been acquired by IV Media LLC. The new owner has conveyed an interest in sustaining a partnership with ChromaDex and continues to purchase in the third and fourth quarter. We have formally asserted a claim for the past due amount totaling approximately $930,000 in the bankruptcy court. Given the uncertainty of the bankruptcy process and our assessment of collectability we placed a reserve on remaining balance of trade receivable with ShopHQ this quarter, which was not material to our overall financial results. We have now reserved the full $930,000 outstanding receivable.

In the context of these developments we are currently supplying to them only on pre-payment terms to sustain the business and mitigate risks to ChromaDex while negotiating with the new owner. As we navigate through this transition the continued success of ShopHQ, TV retail model for Tru Niagen makes us optimistic about a continued partnership. The increased sales from our Tru Niagen business were partially offset by lower Niagen ingredient sales down 21% year-over-year. As you may recall, are ingredient sales surged in the first half of the year, due to the addition of new partners and continued sales from existing partners. Year-to-date, Niagen ingredient sales were up 78% compared to the prior year, and we maintain a positive outlook for Niagen ingredients sales growth for a full year 2023.

Despite some quarter-to-quarter variability. Of note, we face our most challenging ingredient sales comparison in the fourth quarter, since the prior year results included a $2 million upfront minimum purchase from Nestle. Gross margins increased by 160 basis points reaching 61.4%, compared to 59.8% in the third quarter of 2022. The elevated gross margin in the quarter was primarily a result of higher overall sales, allowing us to more efficiently leverage fixed supply chain costs, including labor and other overhead. Additionally, we continue to drive cost savings across the supply chain through optimization efforts and shipping and procurement as well as improvements in yield loss with BMO [ph]. As Rob mentioned, selling and marketing expense as a percentage of net sales decreased the 31% improving 340 basis points compared to 34.4% in the third quarter of 2022.

Research and development expense remain stable compared to the prior year quarter. However, there were two offsetting drivers. First, we had increased investments of approximately $0.4 million to support important R&D initiatives, which were largely offset by a $0.3 million refund related to a discontinued R&D project. We anticipate a further uptick in these R&D investments during the fourth quarter as we ramp up R&D projects, paving the way for new commercial opportunities for ChromaDex in 2024 and beyond. As reported, general and administrative expense decreased $0.3 million compared to the prior year period. The reduction was primarily attributable to lower legal expense, as well as lower severance and restructuring expense. For the third quarter of 2023.

Our operating loss was $1.1 million versus a $3.1 million loss in the third quarter of 2022, an improvement of $1.9 million, largely driven by higher net sales. The net loss attributable to common stockholders for the third quarter of 2023 was $1 million or a loss of $0.01 per share consistent with a net loss of $1 million and a loss of $0.01 per share in the third quarter of 2022. The prior year quarter included a one-time recognition in other income for the employee retention tax credit or ERTC. When the ERTC is excluded, net loss improved $2.1 million, which highlights a clear fundamental improvement in profitability this quarter. Moving to the balance sheet and cash flow, our balance sheet remains strong. We ended the quarter with $26.8 million in cash and no debt.

For the nine months ended September 30 2023 net cash provided by operations was $6.5 million a significant turnaround from the $14.8 million cash outflow in the same period last year. The difference year-over-year was largely driven by improvements in our net loss of $10.1 million. So with changes in working capital primarily related to inventory and prepaid in other assets, which provided positive impacts of $4.1 million and $3 million respectively year-to-date. With shrinking cash flow year-to-date related to inventory was the result of stronger sell through to Try Naigen in our E-commerce channels and to key partners, higher volume of Niagen ingredients sales and more efficient production management. The change in prepaid and other assets is linked to the employee retention tax credit receivable, booked in the prior year period, coupled with collections against these receivable balance in the current year.

For the full year we expect an increase in cash, driven by reduce net loss and improvements in working capital. The trends in the fourth quarter may not be as strong as recent performance, as there is always quarterly variability in investments, inventory production and overall working capital management. As it relates to our 2023 full year P&L outlook, detailed information on key profit and loss metrics can be found in our earnings press release and accompanied by presentation. Overall, all key metrics remain consistent with last quarter's outlook. But we have narrowed our revenue projection as we close out the year and maintaining a conservative approach to our top line outlook, we now expect a 14% to 16% revenue growth year-over-year, driven by our global e-commerce business.

Steady growth from new and existing partnerships, upside realized from new partnerships in the first nine months of 2023, and realistic opportunities in the fourth quarter. This reflects a slight adjustment from our prior guidance of at least 15% primarily to account for a slower recovery of our own website business, as we attempt to scale our spend from the low levels last year while maintaining targeted efficiencies. In addition, we have a pipeline of new business development opportunities with partners as well as an exciting new commercial opportunity of our own, this upside is taking longer to materialize and is more likely to contribute to 2024 results. As it relates to adjusted EBITDA, we remain committed to achieving sustainable profitability, for balancing important strategic investments to drive growth.

For the first nine months of the year, we sustained adjusted EBITDA breakeven or better each quarter and delivered positive $700,000 year-to-date. Looking to the fourth quarter of 2023, we expect negative adjusted EBITDA as we continue to invest in important R&D initiatives, as well as investments in our marketing team to position us for accelerated growth in 2024 and beyond. We anticipate that adjusted EBITDA will be close to breakeven on a full year basis. In summary, this quarter underscores the strength of our resilient business model with double digit net revenue growth, over 60% gross margins and overall cost reductions as we emphasize increased efficiency. Further, it again highlights our capability of delivering cash flow breakeven, having done so for three consecutive quarters and our significantly improved cash position with $26.8 million on our balance sheet and no debt and truly inspired by our achievements in a short amount of time.

I'm confident we can build upon this progress and unlock new revenue opportunities in 2024, which, when coupled with new cost savings initiatives, will enable us to sustain positive adjusted EBITDA. Operator, we are now ready to take questions.

See also Dividend Champions List By Yield and 11 Best Aerospace Stocks To Buy.

To continue reading the Q&A session, please click here.